INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

Professional Services

Resources to help you support your patients. Helpful information, a dedicated patient support liaison, and product samples are all available here.

ORDER SAMPLES

Looking for samples to get your patients started? Order now.

Order Samples  

LITERATURE & HANDOUTS

Download educational resources for health care professionals or patients.

View or Download

PODCARE+

Learn about a centralized support program to help your patients throughout their treatment with TOBI Podhaler.

Savings and Support

CONNECT WITH A REP

Schedule face time with a sales team member.

Connect  

Share

To share this website with other health care professionals, please choose your email service provider:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in
1 second
(FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.